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Abstract 
Background: Methionine sulfoxide reductase A (MsrA) is a potent intracellular oxidoreductase and serves as an 
essential factor that protects cells against oxidative damage. However, therapeutic use of exogenous MsrA in oxida-
tive stress-induced diseases is limited, because it cannot enter the cells. The aim of this study is to investigate whether 
MsrA with PEP-1, a cell penetrating peptide, fused to its N-terminus can protect against oxidative stress in mac-
rophages and can attenuate atherosclerosis in apolipoprotein E deficient (apoE−/−) mice.
Methods: MsrA and the fusion protein PEP-1-MsrA were expressed and purified using a pET28a expression system. 
Transduction of the fusion protein into macrophages was confirmed by Western blot and immunofluorescence 
staining. Intracellular reactive oxygen species (ROS) and apoptosis levels were measured by flow cytometry. In in vivo 
study, MsrA or PEP-1-MsrA proteins were intraperitoneally injected into apoE−/− mice fed a Western diet for 12 weeks. 
Plasma lipids levels, inflammatory gene expression, and paraoxonase-1 (PON1) and superoxide dismutase (SOD) 
activities were assessed. Atherosclerotic lesions were analyzed by Oil Red O staining and immunohistochemistry.
Results: PEP-1-MsrA could penetrate the cells and significantly reduced intracellular ROS levels and apoptosis in 
H2O2-treated macrophages. It also decreased TNFα and IL-1β mRNA levels and increased the IL-10 mRNA level in 
lipopolysaccharide-treated macrophages. In in vivo study, PEP-1-MsrA injection significantly increased plasma PON1 
and SOD activities and decreased plasma monocyte chemoattractant protein 1 (MCP-1) level compared to the injec-
tion of vehicle control or MsrA. In PEP-1-MsrA injected mice, hepatic PON1 levels were increased, while the expression 
of TNFα and IL-6 mRNA in the liver was suppressed. Although plasma total cholesterol and triglyceride levels did not 
change, the aortic atherosclerosis in PEP-1-MsrA treated mice was significantly reduced. This was accompanied by a 
reduction of total and apoptotic macrophages in the lesions.
Conclusion: Our study provides evidence that PEP-1-MsrA may be a potential therapeutic agent for atherosclerosis-
related cardiovascular diseases.
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Background
Cardiovascular disease (CVD), primarily induced by ath-
erosclerosis, is the most common cause of morbidity and 
disability worldwide. Atherosclerosis is now considered a 
chronic inflammatory disease associated with oxidative 
stress and dyslipidemia [1–3]. Numerous studies have 
documented that among the multifactorial causes of ath-
erosclerosis, reactive oxygen species (ROS) play impor-
tant roles in its pathogenesis by stimulating the oxidation 
and modification of lipids and proteins, which can lead to 
foam cell formation and atherosclerotic plaque progres-
sion in the blood vessel wall [4].
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ROS, including superoxide anion, hydroxyl radical 
and hydrogen peroxide (H2O2), are constantly generated 
by cells as byproducts of normal metabolism and highly 
localized within the cells [5, 6]. Cells contain a series 
of antioxidant defenses such as superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase that 
directly detoxify ROS and reduce their effects. The imbal-
ance between ROS generation and the antioxidant sys-
tem in vascular cells occurs due to a change in the overall 
redox balance and in the modification of target mole-
cules, resulting in inflammation and atherogenesis. There 
is increasing evidence that a therapeutic approach target-
ing antioxidant enzymes could decrease the progression 
of atherosclerosis [7].
Sulfur-containing methionine (Met), either free or in 
proteins, is an essential amino acid and a sensitive tar-
get for oxidants. Met is easily oxidized into methionine-
S-sulfoxide (MetSO) which can be reduced back to Met 
by a ubiquitous intracellular enzyme named methionine 
sulfoxide reductase A (MsrA). In turn, oxidized MsrA 
can be reduced by the cellular thioredoxin (Trx), thiore-
doxin reductase and NADPH system [8]. Recent studies 
have demonstrated that MsrA is involved in oxidative 
stress and age associated diseases [9], and enhanced 
MsrA might be an important approach for the preven-
tion of many oxidative stress-induced diseases, such as 
hypoxia/reoxygenation and ischemia/reperfusion injury 
[10, 11], cataracts [12], diabetes mellitus [13], Alzhei-
mer’s disease [14, 15] and atherosclerosis related coro-
nary artery disease [16, 17].
MsrA plays protective roles by maintaining intracellu-
lar redox homeostasis; however, therapeutic use of exog-
enous MsrA is limited, because this enzyme is poorly 
taken up by cells [18]. Cell penetrating peptides (CPPs) 
or protein transduction domains (PTDs) were designed 
to deliver large proteins into mammalian cells [19]. A 
21-amino acid peptide, PEP-1, is a new type of CPP [20], 
and has been reported to be able to successfully trans-
fer a wide range of therapeutic proteins such as SOD 
[21], CAT [22], paraoxonase-1 (PON1) [23] and perox-
iredoxin2 [24] into cells and thus to achieve their intra-
cellular biological activities [25]. Although the precise 
mechanism is as yet unclear, PEP-1 fusion proteins have 
been used in research to protect against many diseases 
including neuronal disease, myocardial ischemic/reper-
fusion injury and skin inflammation [26–28].
The goal of this study is to investigate whether the 
fusion protein PEP-1-MsrA can efficiently enter cells 
to protect against oxidative stress and to attenuate ath-
erosclerosis in apolipoprotein E deficient (apoE−/−) mice, 
providing evidence that PEP-1-MsrA may be a potential 
therapeutic agent for atherosclerosis-related cardiovas-
cular diseases.
Methods
Expression and purification of MsrA and PEP‑1‑MsrA fusion 
protein in E. coli
The plasmid containing the human MsrA cDNA 
sequence without a signal peptide was provided by 
Prof. Stefan H. Heinemann (Jena Friedrich Schiller Uni-
versity, Germany) and the pET15b/PEP-1 plasmid was 
provided by Prof. Jia-Ning Wang (Hubei University of 
Medicine, China). The pET28a vectors were purchased 
from Novagen (Merck Millipore, Germany). To gener-
ate the recombinant pET28a/PEP-1-MsrA vector, a 642-
bp cDNA fragment of human MsrA, digested at BamHI 
and HindIII sites, from pQE30/MsrA was inserted into a 
pET15b/PEP-1 plasmid. Then the PEP-1-MsrA fragment 
was digested at NdeI and HindIII sites and inserted into 
a pET28a vector. A pET28a/MsrA vector was also con-
structed as control. The recombinant vectors were veri-
fied by DNA sequencing.
To produce PEP-1-MsrA or MsrA proteins, plasmids 
were transformed into E. coli BL21 (DE3). The trans-
formed cells were grown in LB medium containing 
10 µg/ml kanamycin at 37 °C to an A600 value of 0.6–0.8 
and induced with 1 mM isopropyl β-d-1-thiogalactoside 
(IPTG) at 30  °C for 4–6  h. Then the bacteria were har-
vested and lysed by a low temperature ultra-high pres-
sure continuous flow cell disrupter (JNBIO, China) in 
lysis buffer (pH 8.0, 50  mM NaH2PO4, 400  mM NaCl, 
10 mM imidazole including with 3 μg/ml lysozyme, 1 μg/
ml DNase I and 5 μM PMSF). The proteins were purified 
by affinity chromatography using Ni-NTA Agarose (Qia-
gen, Germany) according to the manufacturer’s instruc-
tions. The purity was analyzed by 10 % SDS-PAGE with 
Coomassie Blue Staining. Concentrations of the purified 
proteins were determined by the Lowry method using a 
DC protein assay kit (Bio-Rad, USA).
Circular dichroism measurements
Circular dichroism (CD) spectra of proteins were deter-
mined using a Jasco J-810 spectropolarimeter (Jasco 
Corp., Japan) with a 1  mm light-path quartz cell. The 
far-UV CD spectra were recorded from 190 to 250  nm. 
PEP-1-MsrA or MsrA protein solutions were prepared 
at a final concentration of 15 μM in 100 mM phosphate 
buffer (PB, pH 7.5). The averaged spectra of several scans 
were corrected relative to the buffer blank. Measure-
ments were made at room temperature.
MsrA activity assay
MsrA activity was measured using methyl sulfox-
ides (DMSO, Sigma-Aldrich, USA) as a substrate as 
described by Wu [29]. The reaction system (pH 8.0) 
contained 500 μM DMSO, 10  mM MgCl2, 30  mM KCl 
and 50 μM DTT in 25 mM Tris–HCl to which 3.6 μM 
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of the heat-inactivated or active MsrA or PEP-1-MsrA 
was added. To terminate the reaction, 100  μl of reac-
tion mixture and 100  μl of 4  M 5,5′-dithiobis (DTNB, 
Sigma-Aldrich, USA) were added and the mixture was 
incubated for 10 min at 37  °C. The A412 value was then 
recorded at 0 and 10  min after the end of the incuba-
tion period. The decrease in A412 value was calculated 
(ΔA  =  ΔA0min  −  ΔA10min). The heat-inactivated MsrA 
(control) was defined as ΔAControl, while active MsrA 
was named ΔATotal. MsrA activity was calculated using 
the formula: ΔAMsrA = ΔATotal − ΔAControl. PEP-1-MsrA 
activity was normalized with MsrA.
Cell culture
Murine macrophage cell line Raw 264.7 cells and human 
HeLa cells were obtained from the Animal Biosafety 
Level 3 Laboratory (ABSL-III) at Wuhan University, 
China. Mouse peritoneal macrophages were harvested 
by peritoneal lavage 3–4 days after intraperitoneal injec-
tion of 3  ml 3  % thioglycollate [30]. The cells were cul-
tured in Dulbecco’s modified Eagle medium (DMEM, 
ThermoFisher, USA) containing 10 % fetal bovine serum 
(FBS, Gibco, USA) and antibiotics (100  mg/ml strepto-
mycin, 100  U/ml penicillin, Beyotime, China) at 37  °C. 
Cells were seeded in plates and incubated with serum-
free DMEM at 37 °C overnight before further treatment.
Transduction of PEP‑1‑MsrA protein into cells
MTT method was performed to test the cytotoxicity of 
the proteins. HeLa cells were treated with MsrA or PEP-
1-MsrA (0–18 μM) for 72 h. To determine the transduc-
tion efficiency of PEP-1-MsrA, peritoneal macrophages 
were treated with various concentrations of PEP-1-MsrA 
or MsrA protein (0.5–8  μM) for 1  h. Then cells were 
washed with PBS and harvested for Western blot analy-
sis. The cells were also treated with 1 μM of proteins for 
various times (5  min–24  h) to examine the stability of 
PEP-1-MsrA by Western blot analysis.
We further detected the intracellular distribution of 
transduced protein using an immunofluorescence assay. 
Briefly, peritoneal macrophages were seeded on cover-
slips and treated with selected concentrations of PEP-
1-MsrA or MsrA protein (1–4  μM) for 1  h, and then 
washed with PBS at least three times and fixed with 4 % 
paraformaldehyde for 10  min at 37  °C. The cells were 
incubated with the primary antibody (anti-MsrA anti-
body, Abcam, USA) overnight at 4  °C, then with FITC-
conjugated goat anti-rabbit IgG (1:200) for 2  h at room 
temperature in the dark. Nuclei were stained with 
300 nM DAPI (Sigma-Aldrich, USA) for 15 min at 37 °C. 
The intracellular localization of MsrA protein was ana-
lyzed with confocal microscopy (Olympus FluoView 
FV1000, Japan).
Determination of intracellular ROS levels
Intracellular ROS levels were detected by the sensi-
tive fluorescent dye 2′,7′-dichlorofluorescin diacetate 
(DCFH-DA, Sigma-Aldrich, USA) as described in previ-
ous studies [23, 28]. RAW264.7 cells were pre-incubated 
with PEP-1-MsrA or MsrA protein (1 µM) for 1 h, and 
then exposed to 1 mM H2O2 for 1 h. After washing with 
PBS, cells were incubated with 20  µM DCFH-DA for 
30  min at 37  °C. The DCF fluorescence intensity was 
measured by flow cytometry (FACS Aria™ III system, 
BD, USA).
Cell death assays
Cell death was detected by Annexin V and propidium 
iodide (PI) binding assay. Peritoneal primary mac-
rophages were pre-treated with PEP-1-MsrA and MsrA 
protein (1 µM) for 1 h before incubated with 1 mM H2O2 
for 1  h. Cells were resuspended in Annexin-V binding 
buffer and incubated with Annexin V-FITC and PI for 
15 min at room temperature, according to the procedure 
for the Annexin-V-fluorescein (Annexin-V-FITC) Apop-
tosis Detection Kit (Bestbio, China). Total cell death was 
analyzed by flow cytometry.
Western blot analysis
Harvested cells or frozen tissues were lysed by RIPA 
(Beyotime Institute of Biotechnology, China) with 1  % 
proteinase inhibitors (Roche, Germany) for Western blot 
analysis. Appropriate amounts of proteins were loaded 
and separated by 10  % SDS-PAGE and transferred onto 
a nitrocellulose membrane. Protein expression was 
detected using primary antibodies, anti-MsrA antibody 
or anti-PON1 antibody (Abcam, USA) (1:1000), followed 
by horseradish peroxidase (HRP)-conjugated secondary 
antibody (Santa Cruz Biotechnology, USA) (1:10,000). 
Signal was detected using an enhanced chemilumines-
cence kit (ECL, GE Healthcare, USA). The band densi-
tometry was analyzed with Image J software (NIH, USA).
Quantitative real‑time PCR (qPCR)
Mouse peritoneal macrophages were co-cultured with 
25 ng/ml LPS and 1 µM PEP-1-MsrA or MsrA proteins 
for 3  h, and then harvested with Trizol reagent (Invit-
rogen, USA). Mouse liver tissue was also homogenized 
with Trizol reagent. Total RNA was extracted using an 
RNeasy kit (Qiagen, Germany) and reverse transcribed 
into cDNA using a PrimerScript® RT reagent Kit with 
gDNA Eraser (TaKaRa, Japan). Target mRNA levels 
were measured by qPCR with the CFX96 Touch™ Real-
Time PCR Detection System (Bio-Rad, USA) accord-
ing to the manufacturer’s instructions. Mouse genes 
were normalized with 18s RNA as an endogenous con-
trol. Primers used were as follows: mouse 18s RNA: 5′ 
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CGCGGTTCTATTTTGTTGGT 3′ (forward) and 5′ AG 
TCGGCATCGTTTATGGTC 3′ (reverse); mouse IL-1β: 
5′ GCCCATCCTCTGTGACTCAT 3′ (forward) and 5′ 
AGGCCACAGGTATTTTGTCG 3′ (reverse); mouse 
TNFα: 5′ CGTCAGCCGATTTGCTATCT 3′ (forward) 
and 5′ CGGACTCCGCAAAGTCTAAG 3′ (reverse); 
mouse IL-10: 5′ AGCCTTATCGGAAATGATCCAGT 3′ 
(forward) and 5′ GGCCTTGTAGACACCTTGGT 3′ 
(reverse); mouse PON1: 5′ TGGTGGTAAACCATCCAG 
ACTC 3′ (forward) and 5′ TGTGATGGTTTTCAGATG 
CAAG 3′ (reverse); and mouse IL-6: 5′ AGTTGCCTTC 
TTGGGACTGA 3′ (forward) and 5′ TCCACGATTTCCC 
AGAGAAC 3′ (reverse).
Mice
ApoE−/− mice on a C57BL/6 background were pur-
chased from Vital River Laboratory Animal Technology 
Company, China, and housed in microisolator cages in 
the Wuhan University Animal Center. Mice were fed in 
a temperature-controlled facility (temperature 22 ± 1 °C, 
humidity 60 %, 12 12-h dark-light cycle) with free access 
to food and water. Animal care and experimental pro-
cedures were performed under the regulations of the 
Institutional Animal Care and the Ethics Committee for 
Animal Experiments of Wuhan University, in accord-
ance with the Guidelines for the Care and Use of Labora-
tory Animals of the Chinese Animal Welfare Committee. 
Thirty male apoE−/− mice at 21  weeks of age were ran-
domly divided into three groups and intraperitoneally 
injected with one of the two target proteins (dose of 
5.5  nmol per mouse every 36  h) or 10  mM phosphate 
buffered saline (PBS, pH 7.4), respectively. Mice were fed 
with AIN76A Western diet (HFK bioscience company, 
China) for 12  weeks to accelerate the development of 
atherosclerosis.
Determination of biochemical parameters in plasma 
and liver
Blood samples were collected from mice after overnight 
fasting by retro-orbital venous plexus puncture at 4 week 
intervals. Plasma was immediately separated by cen-
trifugation at 10,000×g for 10 min at 4 °C. Total choles-
terol (TC) and triglyceride (TG) levels in fresh plasma 
were measured by enzymatic colorimetric assay kits 
(Mind Bioengineering, China). The remaining plasma 
was stored at −80  °C for other analysis. Plasma MCP-1 
levels were determined by enzyme-linked immunosorb-
ent assay (ELISA) kits (eBioscience, USA) according to 
the manufacturer’s instructions. Plasma PON1 activ-
ity was measured using paraoxon (Sigma-Aldrich, USA) 
as a substrate as described previously [31]. Plasma SOD 
activity was measured using SOD Detection Kit (Nan-
jing Jiancheng Bioengineering Institute, China). Frozen 
mouse liver samples were lysed by RIPA with 1 % protein-
ase inhibitors for Western blot analysis. Liver homogen-
ates treated with Trizol reagent were used for qPCR 
analysis of target mRNA levels.
Histochemical and immunocytochemical analyses 
of atherosclerotic lesions
Mice were intraperitoneally injected with either proteins 
or PBS at 36 h intervals for 12 weeks, then sacrificed 2 h 
after the last of these injections. The aortic roots were 
embedded in OCT (SAKURA, USA) and quickly frozen 
to −20  °C; then 8-μm serial sections of the aortic root 
were collected for atherosclerosis analysis. Aortas fixed in 
4 % paraformaldehyde were analyzed en face. The extent 
of atherosclerosis was determined by Oil Red O staining 
and quantification with Image J software as described 
previously [32].
The location of MsrA in the aortic root was detected by 
immunofluorescence staining with anti-MsrA antibody. 
Rat anti-mouse monocytes/macrophage antibody-2 
(MOMA2, Bio-rad, USA) was used for macrophage 
detection in the aortic root. Immunoreactivity was visu-
alized using the Vectastain ABC kit (Vector Labs, USA) 
and then reacted with DAB substrate (ZSGB-BIO, China). 
Analysis of apoptosis in aortic root tissue was performed 
using the terminal deoxynucleotidyl transferase-medi-
ated dUTP nickend-labeling assay kit (TUNEL, Roche 
Diagnostics, Germany) according to the manufacturer’s 
instructions. The TUNEL positive cells were counted and 
normalized to the cell totals. MOMA-2 staining area and 
apoptosis were analyzed with Image-Pro Plus 6.0.
Statistical analysis
Data are represented as the mean  ±  SEM. Statistical 
analyses were performed using Student’s t test and one-
way ANOVA between the groups. Differences were con-
sidered to be significant at P < 0.05.
Results
Purified PEP‑1‑MsrA had similar structure and enzyme 
activity to MsrA
Recombinant pET28a/MsrA and pET28a/PEP-1-MsrA 
plasmids were constructed (Additional file 1: Figure S1). 
PEP-1-MsrA or MsrA proteins were highly expressed in 
E. coli BL21 (DE3) induced by IPTG and were purified 
from bacteria extracts using Ni-NTA affinity chromatog-
raphy. The purified proteins were checked by 10 % SDS-
PAGE and shown to be more than 95 % purity (Fig. 1a). 
MsrA proteins were confirmed by Western blot (Fig. 1b). 
The molecular weights of MsrA and PEP-1-MsrA are ~27 
and ~30 kDa, respectively.
To determine whether fusion with PEP-1 could alter 
the structure of MsrA, we compared the secondary 
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structural features of PEP-1-MsrA and MsrA by far-UV 
CD. Both PEP-1-MsrA and MsrA adopt a predominantly 
α-helix conformation with double minima at 208 and 
222  nm and have similar α-helix contents (17.1  % for 
PEP-1-MsrA and 18.1  % for MsrA) (Fig.  1c), suggesting 
that the fusion with PEP-1 does not change the structure 
of MsrA.
We also compared the enzyme activity of purified 
PEP-1-MsrA to that of MsrA. The enzyme activity of 
PEP-1-MsrA appeared to be slightly higher than that of 
MsrA, but the difference was not statistically significant 
(Fig. 1d), indicating that the fusion with PEP-1 does not 
compromise the function of MsrA.
Transduction of PEP‑1‑MsrA into macrophages
The cytotoxicity of proteins was tested on HeLa cells 
using the MTT method. We found that even at con-
centrations up to 18  μM, neither purified MsrA nor 
PEP-1-MsrA protein reduced cell viability (Additional 
file 2: Figure S2). We selected 0.5–8 μM purified protein 
to determine the transduction ability and intracellular 
stability of PEP-1-MsrA protein. As shown in Fig.  2a, 
PEP-1-MsrA protein could successfully enter the cells in 
a dose-dependent manner, whereas control MsrA pro-
tein did not enter the cells. Also, peritoneal macrophages 
were treated with 1 μM PEP-1-MsrA proteins; the pres-
ence of PEP-1-MsrA protein was maintained for more 
than 24 h in the cells (Fig. 2b).
In addition, the intracellular distribution of trans-
duced PEP-1-MsrA was detected by confocal micros-
copy. As shown in Fig.  2c, PEP-1-MsrA protein was 
detected in the cytoplasm, and immunofluorescence 
was increased in a concentration dependent manner, 
whereas MsrA protein was not detected in macrophages 












3      4       5      6
PEP-1-MsrA
MsrA
Fig. 1 Purification and identification of PEP-1-MsrA and MsrA protein. a Expression and purification of the fusion proteins were analyzed by 10 % 
SDS-PAGE. 1 Non-induced MsrA, 2 non-induced PEP-1-MsrA, 3 induced MsrA, 4 induced PEP-1-MsrA, 5 purified MsrA, 6 purified PEP-1-MsrA. b MsrA 
expression in E. coli were detected by Western blot. c CD spectra of the pure proteins. d MsrA activity was measured using DMSO as the substrate
Page 6 of 13Wu et al. J Transl Med  (2015) 13:316 
PEP‑1‑MsrA inhibited H2O2 induced oxidation and cell 
death of macrophages
To determine the effects of transduced PEP-1-MsrA on 
oxidative stress, RAW264.7 cells were pre-treated with 
1 µM PEP-1-MsrA or MsrA proteins for 1 h followed by 
treatment with 1 mM H2O2. ROS levels were then meas-
ured. As shown in Fig.  3a, H2O2 treatment resulted in 
high ROS levels in the cells. ROS production was mark-
edly reduced in the cells pre-treated with PEP-1-MsrA, 
but was not changed by MsrA pre-treatment. We also 
examined the impact of PEP-1-MsrA on cell survival 
under H2O2 induced oxidative stress using peritoneal 
macrophages. Compared to MsrA treated cells, cells 
treated with PEP-1-MsrA showed a remarkable reduc-
tion in apoptosis and necrosis (Fig.  3b), indicating that 
intracellular PEP-1-MsrA could protect macrophages 
from H2O2-induced cell death by reducing intracellular 
ROS levels.
PEP‑1‑MsrA suppressed LPS induced inflammation 
in macrophages
To investigate the effects of intracellular MsrA on inflam-
matory responses, mouse peritoneal macrophages were 
pre-treated with PEP-1-MsrA or MsrA and then treated 
with LPS to induce inflammatory responses. In PEP-1-
MsrA pre-treated cells, LPS-induced expression of the 
proinflammatory cytokines IL-1β and TNFα was sig-
nificantly inhibited, while the expression of anti-inflam-
matory cytokine IL-10 was increased compared to the 
respective levels in MsrA pre-treated cells (Fig.  3c–e), 
b








1 µM   2 µM 4 µMControl              MsrA 4 µM
c




Fig. 2 PEP-1-MsrA was transduced into macrophages. Mouse peritoneal macrophages was incubated with PEP-1-MsrA or MsrA (0.5–8 μM) for 1 h 
(a) and 1 μM protein for various times (5 min–24 h) (b), then the intracellular MsrA was analyzed by Western blot. c The intracellular distribution of 
PEP-1-MsrA or MsrA in macrophages was determined by confocal microscopy. FITC-conjugated antibody was used for immunofluorescence assay 
and micrographs were captured at ×1000 magnification
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indicating that intracellular PEP-1-MsrA significantly 
suppressed the macrophage inflammatory response.
PEP‑1‑MsrA ameliorated inflammatory and oxidative stress 
in apoE−/− mice
ApoE−/− mice were intraperitoneally injected with MsrA, 
PEP-1-MsrA proteins or vehicle and fed a Western-diet 
for 12 weeks. The body weights (at various time-points) 
and spleen weights (at the end point) of mice showed no 
difference between all three groups (Additional file 3: Fig-
ure S3). Plasma PON1 and SOD activities are the indi-
cators of anti-oxidative status in circulation. We found 
that plasma PON1 and SOD activities were significantly 
increased, while the plasma inflammatory factor MCP-1 
level was decreased in PEP-1-MsrA injected mice com-
pared to the respective levels in control mice or MsrA 
injected mice (Fig. 4a–c).
The liver is an important organ for the regulation of 
oxidative and inflammatory status. PON1 is an HDL-
associated antioxidase that is mainly synthesized in 
liver. We found that mRNA and protein levels of PON1 
in liver tissue were significantly increased in PEP-1-
MsrA injected mice compared to those of MsrA injected 
or control mice. This is consistent with the high level 
of MsrA in the livers of PEP-1-MsrA injected mice 
(Fig. 4d, e). Meanwhile, the mRNA levels of inflammatory 
cytokines TNFα and IL-6 were significantly decreased 
in PEP-1-MsrA treated mice (Fig.  4f ). These data indi-
cate that when PEP-1-MsrA enters the cells in the liver, 
it plays an anti-oxidative and anti-inflammatory role 
through upregulating PON1 expression and inhibiting 
the expression of inflammatory cytokines. These data 
demonstrated that transduced PEP-1-MsrA improved 
circulation and hepatic anti-oxidative and anti-inflamma-
tory status in apoE−/− mice.
PEP‑1‑MsrA attenuated atherosclerosis in apoE−/− mice
During the treatment with purified proteins and West-
ern-diet feeding, the plasma TC and TG levels were 
not significantly different between the three groups 
(Table  1). The impact of PEP-1-MsrA injection on the 
development of atherosclerosis in apoE−/− mice was 
Fig. 3 PEP-1-MsrA inhibited oxidation, cell death and inflammation in macrophages. a Intracellular ROS levels were measured by flow cytom-
etry. RAW264.7 macrophages were pretreated with PEP-1-MsrA or MsrA (1 µM) and stimulated by 1 mM H2O2 for 1 h. b The apoptosis of mouse 
peritoneal macrophages induced by H2O2 was quantified by flow cytometry. c–e The mRNA levels of inflammation-associated cytokines IL-1β, TNFα 
and IL-10 were determined by q-PCR. Mouse peritoneal macrophages were treated with 25 ng/ml LPS, and 1 µM PEP-1-MsrA or MsrA for 3 h before 
mRNA was extracted. n = 3–4 for each group, *P < 0.05, **P < 0.01 vs control group. #P < 0.05, ##P < 0.01 vs LPS-induced group. ΔP < 0.05, ΔΔP < 0.01 
vs MsrA-treated group
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assessed. Representative atherosclerotic lesions in cross-
sections of aortic roots and en face aorta images stained 
with Oil Red O are shown in Fig. 5a, b. The lipid stain-
ing area in the lesion of PEP-1-MsrA injected mice 
(0.32 ± 0.02 mm2) was significantly smaller than that in 
control mice (0.40 ±  0.02  mm2) or MsrA injected mice 
(0.38  ±  0.03  mm2), reduced by 20 and 16  % respec-
tively (P  <  0.01 or P  <  0.05, Fig.  5c). En face analysis of 
pinned-out aortas revealed that the percent area of ath-
erosclerotic lesion in PEP-1-MsrA injected mice was also 
significantly reduced compared to MsrA injected mice 
and control mice (P < 0.01, Fig. 5d).
We found that higher levels of MsrA were detected 
in the arterial walls of PEP-1-MsrA injected mice com-
pared to those in the control and MsrA groups, indicat-
ing that PEP-1-MsrA successfully entered the cells of 
aorta (Fig. 6a). We further stained macrophages in aortic 
root lesions using a mouse macrophage specific antibody, 
MOMA2, and found the PEP-1-MsrA injected mice 
displayed 28  % smaller macrophage areas compared to 
control mice (0.28 ± 0.01 vs 0.39 ± 0.01 mm2) and 20 % 
smaller macrophage areas compared with MsrA injected 
mice (0.35  ±  0.02  mm2) (Fig.  6b). In addition, there 
were 46 % fewer apoptotic cells in the aortic root cross-
sections of PEP-1-MsrA injected mice than in those of 
control mice and 48 % fewer than in MsrA injected mice 
(Fig.  6c). These data show that PEP-1-MsrA attenuates 
the development of atherosclerosis in apoE−/− mice by 
reducing the accumulation of macrophages, especially 
apoptotic macrophages, in the lesions.
Discussion
Intracellular redox status is tightly regulated by oxi-
dant and antioxidant systems. An imbalance between 
these systems causes ROS accumulation which leads to 
oxidative stress and inflammation. It has been shown 
that ROS-induced oxidation is a well-known cause of 
atherogenesis and is involved in every step of athero-
sclerosis development, including vascular endothelial 
cell injury, macrophage chemotaxis, foam cell formation 
Fig. 4 PEP-1-MsrA ameliorated oxidation and inflammation in the plasma and the liver of apoE−/− mice. The 21-week-old apoE−/− mice were 
fed a Western diet and intraperitoneally injected with PBS, MsrA or PEP-1-MsrA proteins for 12 weeks. a, b Plasma PON1 and SOD activities were 
determined, n = 8–10. c Plasma MCP-1 level was detected by ELISA, n = 10. d MsrA and PON1 levels in the liver were determined by Western blot. 
e PON1 mRNA levels in mice liver were measured by qPCR. f The mRNA levels of TNFα and IL-6 in mice liver were measured by qPCR. All tests were 
analyses of three independent experiments (n = 4–5). *P < 0.05, **P < 0.01 vs control group, ΔP < 0.05, ΔΔP < 0.01 vs MsrA group
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and smooth muscle cell migration and proliferation [33]. 
Many research efforts have been made without much 
success to develop a therapeutic approach for atheroscle-
rosis through regulating the redox status by improving 
the efficacy of antioxidant enzymes.
MsrA, one of the antioxidant defenses in cells, is impor-
tant in the maintenance of redox homeostasis and in the 
prevention of oxidative stress-related disease. MsrA is 
distributed in the cytoplasm, mitochondria and nuclei 
and is involved in regulating the redox state and the func-
tion of numerous proteins, for examples, calmodulin, 
apolipoprotein AI, IL-6, interferon and cytochrome c 
oxidase [34]. Studies have shown that MsrA activity was 
significantly reduced in the brains of Alzheimer’s disease 
Table 1 Plasma lipids levels in apoE−/− mice
Data are given as the mean ± SEM, n = 10. The statistical analysis was performed using a two-tailed Student’s t test. Mice were fed a Western-type diet and 
intraperitoneally injected with PBS, MsrA or PEP-1-MsrA proteins for 12 weeks
TC total cholesterol, TG triglycerides
Time (weeks) Control MsrA PEP‑1‑MsrA
TC (mg/dL) 0 522.9 ± 89.1 561.6 ± 76.6 528.0 ± 28.1
4 696.7 ± 116.9 727.1 ± 92.8 699.7 ± 83.7
8 824.6 ± 67.5 809.1 ± 126.9 863.8 ± 143.1
12 888.6 ± 75.7 929.9 ± 91.7 867.3 ± 119.1
TG (mg/dL) 0 127.4 ± 19.7 139.3 ± 25.4 137.7 ± 21.3
4 170.4 ± 20.7 164.9 ± 22.0 168.3 ± 16.1
8 188.0 ± 30.7 206.2 ± 40.4 192.6 ± 35.7
12 191.5 ± 41.5 185.3 ± 30.0 194.3 ± 30.6
Fig. 5 PEP-1-MsrA reduced atherosclerotic lesions in apoE−/− mice. The atherosclerotic lesions was examined using Oil Red O-stained cross-sec-
tions of the aorta root (8-µm serial sections) and by en face analysis of the aorta. a, b Representative lesions in cross-sections of the aorta root and en 
face aortas. c, d The atherosclerotic lesion areas were quantified with Image J software
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patients and in the cardiomyocytes in cardiac ischemia 
models [35, 36]. E. coli and yeast with MsrA mutations or 
deficiency were particularly sensitive to oxidative damage 
[37, 38]. MsrA knockout mice are highly sensitive to oxi-
dative stress and show nerve damage and shortened lifes-
pans [39]. Whereas MsrA transgenic Drosophila show 
significantly enhanced anti-oxidation and anti-aging 
characteristics [40]. However, whether or not MsrA 
could be used as a therapeutic agent for atherosclerosis 
has not been investigated.
Due to their size and low permeability, it is usually diffi-
cult for foreign proteins to enter cells and perform intra-
cellular functions [18]. A recent report showed that the 
21-residue PEP-1 peptide is a new type of amphipathic 
CPP [20]. Several PEP-1 fusion proteins, such as PEP-1-
SOD, PEP-1-CAT, PEP-1-SIRT2 and PEP-1-PON1, have 
been designed; and studies have demonstrated that PEP-1 
is a promising tool that may help in the development of 
potential protein therapeutic agents against oxidative 
stress [21–23, 28]. We constructed a PEP-1-MsrA fusion 
protein in order to deliver MsrA into cells and allow it to 
regenerate its reductase activity using the intrinsic cel-
lular Trx reduction system. We found that MsrA, fused 
with a PEP-1 peptide, was able to efficiently enter mac-
rophages with regular incubation. Lee et  al. recently 
reported that a similar fusion protein of MsrA could 
rapidly enter keratinocytes and play a protective role 
against oxidative stress and ultraviolet radiation-induced 
cell death [41]. Interesting, they found that their fusion 
protein was truncated in the N-terminal region of MsrA 
between Lys-27 and Val-28 during expression in E. coli 
and purification. MsrA in our study was designed to 
cleave off N-terminal domain of mitochondrial target-
ing signal peptide, so we did not observe the phenom-
enon of MsrA protein truncation in  vitro. Our study 
showed that PEP-1-MsrA entered into macrophages and 
exerted the anti-oxidative and anti-inflammatory func-
tions through decreasing intracellular ROS levels. Also 
Fig. 6 PEP-1-MsrA reduced macrophage infiltration and cell apoptosis in the lesions. a The MsrA level in the aortic lesions was detected by immu-
nofluorescence assay. b The macrophages in aortic root lesions were visualized by Immunostaining for MOMA-2 and MOMA-2 staining area was 
analyzed with Image-Pro Plus 6.0. c Apoptosis in lesions was detected by TUNEL assay. The apoptotic cells were counted and normalized to the total 
number of cells in the lesion area
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of note, PEP-1-MsrA suppressed LPS-induced expres-
sion of the proinflammatory cytokines TNFα and IL-1β 
and increased expression of the anti-inflammatory 
cytokine IL-10  [42], suggesting that intracellular MsrA 
could inhibit M1 polarization of macrophages under pro-
inflammatory stimulations.
In the in vivo study, we injected purified PEP-1-MsrA 
proteins into apoE−/− mice fed a Western diet. ApoE−/− 
mice have been widely used as an atherosclerotic mice 
model due to the development of spontaneous hyper-
cholesterolemia and atherosclerosis, which can be accel-
erated by high fat diet feeding. We found that injection 
of PEP-1-MsrA could significantly reduce the size of 
atherosclerotic lesions without altering plasma lipid lev-
els, but injection of MsrA did not affect atherosclerosis. 
These results suggest that the anti-oxidative and anti-
inflammatory effects of cell penetrating PEP-1-MsrA 
confer anti-atherogenic benefit to the hyperlipidemic 
mice through lipid-independent mechanisms. In fact, 
our results showed that PEP-1-MsrA injection increased 
mouse plasma PON1 and SOD activities and decreased 
plasma MCP-1 levels. PON1 is mainly synthesized in the 
liver and secreted to the plasma where it is mainly asso-
ciated with HDL particles. Our previous study indicated 
the negative correlation between the activity of plasma 
PON1 and the extent of atherosclerosis [31]. SOD is 
another important protein that maintains redox homeo-
stasis. A recent study reported that Met/MetSO modified 
liver homeostasis and altered the redox state by increas-
ing the activity of SOD [43]. Our results further demon-
strated that accumulation of PEP-1-MsrA in the liver led 
to an increase in hepatic PON1 mRNA and protein lev-
els, indicating that PEP-1-MsrA may enter hepatocytes 
and up-regulate PON1 expression. In the meantime, the 
expression of inflammatory cytokines TNFα and IL-6 
was also reduced in the liver of the PEP-1-MsrA injected 
mice. Interestingly, the injection of MsrA, although 
largely ineffective, indeed also increased plasma SOD 
activity and reduced hepatic IL-6 expression. These data 
indicate the extracellular MsrA may exert mild anti-oxi-
dative and anti-inflammatory function in the liver, but 
not robust enough to reduce atherosclerosis.
Another important mechanism by which PEP-1-MsrA 
reduces atherosclerosis, however, may lie in its effects 
on macrophages. First, our in  vitro data clearly showed 
that PEP-1-MsrA could effectively enter macrophages 
and exert anti-oxidative and anti-inflammatory func-
tion as mentioned earlier. Second, PEP-1-MsrA injec-
tion reduced plasma MCP-1 levels. Although we do 
not know in what organs and cell types MCP-1 produc-
tion was inhibited by PEP-1-MsrA, the reduced plasma 
MCP-1 levels would lead to reduced monocyte/mac-
rophage infiltration to the arterial wall [44]. Third, in 
fact, macrophage content in the lesions of PEP-1-MsrA 
injected mice was significantly reduced. Fourth, more 
interestingly, the apoptotic macrophages were even more 
reduced in lesions of PEP-1-MsrA injected mice than 
total macrophages, suggesting the apoptosis-preventive 
function of PEP-1-MsrA shown in  vitro also operated 
in the atherosclerotic lesions; and actually PEP-1-MsrA 
protein was detected enriched in the lesions.
Conclusions
MsrA, as a specific intracellular MetSO reductase, plays 
an important role in redox homeostasis. Our studies indi-
cate that PEP-1-MsrA effectively enter cells and plays a 
protective role against oxidative stress and inflammation. 
In Western diet-fed apoE−/− mice model, administra-
tion of this protein could significantly halt atherogenesis 
through increasing the anti-oxidative and anti-inflam-
matory capacity in the liver and reducing macrophage 
accumulation, inflammatory responses, and apoptosis in 
the lesions. Therefore, PEP-1-MsrA may be developed as 
a potent therapeutic agent for reducing atherosclerosis-
related cardiovascular diseases.
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